Fred Hutch Cell Therapy Lab

Seattle, WA
National Center
CAR-T Cell Therapy
527 confirmed programs · 67 sponsors · Last scored 2026-03-15
63.0
Signal Score
○ FDA Inspections ✓ Clinical Trials (527) ○ SEC Filings ○ Press

Quick Facts: Fred Hutch Cell Therapy Lab

Signal Score
63.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Seattle, WA
Modalities
CAR-T, Cell Therapy
Active CGT Programs
527 confirmed from ClinicalTrials.gov across 67 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs 527
Sponsors67
ModalitiesCAR-T, Cell Therapy
527 active programs across 67 sponsors
Modalities: CAR-T, Cell Therapy
394 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting
NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation... PHASE1/PHASE2 Not Yet Recruiting
NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment... PHASE2 Not Yet Recruiting
NCT05621291 A Study to Evaluate Next-Generation Sequencing (NGS) Testing... NA Recruiting
NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell... PHASE2 Recruiting
NCT06983899 Exercise Training for the Improvement of Immune Activity and... NA Recruiting
NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for... PHASE1 Recruiting
NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy... PHASE1/PHASE2 Recruiting
NCT06817889 Remdesivir for the Treatment of Upper Respiratory Tract... PHASE2 Recruiting
NCT07052630 Patient Navigation and the Planning Advance Care Together... NA Recruiting
View all 527 programs →
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Financial Stability 68.0
Parent company: Fred Hutchinson Cancer Center
Financial assessment: 68.0/100
Source: SEC EDGAR, press monitoring
Subsidiary of Fred Hutchinson Cancer Center
SEC FilingsParent: Fred Hutchinson Cancer Center
Parent company: Fred Hutchinson Cancer Center
Financial assessment: 68.0/100
Capacity 58.0
1 CGT manufacturing site: Seattle, WA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Seattle, WA
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
1 CGT manufacturing site: Seattle, WA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100

Clinical Activity 527 studies

NCT04579523 ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With... PHASE1 Not Yet Recruiting NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor... PHASE1/PHASE2 Not Yet Recruiting NCT07194980 Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of... PHASE2 Not Yet Recruiting NCT05621291 A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring... NA Recruiting NCT07228624 Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older... PHASE2 Recruiting NCT06983899 Exercise Training for the Improvement of Immune Activity and Treatment... NA Recruiting NCT07227571 Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of... PHASE1 Recruiting NCT07098364 ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in... PHASE1/PHASE2 Recruiting NCT06817889 Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV... PHASE2 Recruiting NCT07052630 Patient Navigation and the Planning Advance Care Together Website to Improve... NA Recruiting NCT06947928 Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In... PHASE2/PHASE3 Recruiting NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by... PHASE2 Recruiting NCT06752694 Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After... PHASE2 Recruiting NCT06928662 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body... PHASE1/PHASE2 Recruiting NCT06839053 Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With... PHASE2 Recruiting NCT06094842 Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific... PHASE1 Withdrawn NCT05936229 Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR... PHASE1/PHASE2 Withdrawn NCT06609928 FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric... PHASE1 Recruiting NCT06236139 Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients... PHASE1/PHASE2 Recruiting NCT06559709 A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple... NA Completed
+ 507 more studies
Source: ClinicalTrials.gov · Retrieved Mar 20, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs →